« Biosimilars: Supreme Court Calls for Solicitor General’s Views in Amgen v. Sandoz | Main | Will the Supreme Court Review Whether FDA-Mandated Bioequivalence Testing to Maintain Approval Falls Within the § 271(e)(1) Safe Harbor? »

07/20/2016

Comments